In a recent study, researchers assessed the effectiveness and safety of trastuzumab deruxtecan, a drug targeting HER2 with a topoisomerase I inhibitor payload, in treating patients with HER2-expressing uterine carcinosarcoma (UCS). Patients who had recurrent UCS with HER2 scores of ≥1+ and had been previously treated with chemotherapy were given trastuzumab deruxtecan intravenously every 3 weeks. Objective response rates were 54.5% for HER2-high and 70.0% for HER2-low groups when reviewed centrally. Researchers concluded that trastuzumab deruxtecan is effective for UCS patients, irrespective of their HER2 status, and side effects were controllable with careful monitoring and treatment.
Reference: Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. J Clin Oncol. 2023;41(15):2789-2799. doi: 10.1200/JCO.22.02558.
